TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Long Term, Open Label, Randomised Study in Patients With Type 2 Diabetes, Comparing the Combination of Rosiglitazone and Either Metformin or Sulfonylurea With Metformin Plus Sulfonylurea on Cardiovascular Endpoints and Glycaemia
Brief Summary: This study is a phase 3b, multicentre, randomised, open label, parallel group study. A 4-week run-in period will be followed by a median of 6 years of treatment with study medication in addition to continuation of background glucose lowering therapy. Patients inadequately controlled on background metformin will be randomised to receive, in addition to metformin, either rosiglitazone or a sulfonylurea(glibenclamide, gliclazide or glimepiride) in a ratio of 1:1. Patients inadequately controlled on background SU will be randomised to receive, in addition to SU, either rosiglitazone or metformin in a ratio of 1:1. Equal numbers of patients receiving background metformin and SU at entry will be entered into the study.


Options:
A: Arm Label: Exemestane; Type: OTHER; Interventions: Drug: exemestane | Intervention Type: DRUG; Name: exemestane; Assigned to Arm(s): Exemestane
B: Intervention Type: DRUG; Name: Zoledronic Acid; Assigned to Arm(s): N/A
C: Arm Label: rosiglitazone in addition to background metformin; Type: EXPERIMENTAL; Interventions: Drug: Rosiglitazone, Drug: Metformin | Arm Label: rosiglitazone in addition to background sulfonylurea; Type: EXPERIMENTAL; Interventions: Drug: Rosiglitazone, Drug: Sulfonylurea | Arm Label: Sulfonylurea in addition to background metformin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sulfonylurea, Drug: Metformin | Arm Label: Metformin in addition to background sulfonylurea; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sulfonylurea, Drug: Metformin | Intervention Type: DRUG; Name: Rosiglitazone; Assigned to Arm(s): rosiglitazone in addition to background metformin, rosiglitazone in addition to background sulfonylurea | Intervention Type: DRUG; Name: Sulfonylurea; Assigned to Arm(s): Metformin in addition to background sulfonylurea, Sulfonylurea in addition to background metformin, rosiglitazone in addition to background sulfonylurea | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Metformin in addition to background sulfonylurea, Sulfonylurea in addition to background metformin, rosiglitazone in addition to background metformin
D: Intervention Type: DRUG; Name: hormone replacement therapy; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: estrogens; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: progestins; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: estrogen replacement therapy; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: diet, fat-restricted; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: calcium; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: vitamin D; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: dietary supplements; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The AESOPUS Study: Ultrasound Findings to Adjust the Duration of Anticoagulation in Patients With Deep Vein Thrombosis
Brief Summary: Prospective controlled randomized clinical trial. Consecutive patients with acute proximal deep vein thrombosis (DVT) of the lower extremities, with or without contemporary manifestations of pulmonary embolism, are randomized to receive either a fixed duration of anticoagulant therapy (three months in patients with DVT secondary to transitory risk factors, six months in patients with idiopathic DVT) or a flexible duration of anticoagulant therapy, according to the persistence of residual thrombi, as shown by leg veins ultrasonography (up to 1 year in patients with secondary DVT, up to 2 years in those with idiopathic DVT). All patients are followed up to three years to assess the development of (objectively documented) recurrent thromboembolism. The rate of recurrent thromboembolism is compared between the two study groups, as well as the rate of major bleeding complications occurring during anticoagulation.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: sodium warfarin | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: sodium warfarin | Intervention Type: DRUG; Name: sodium warfarin; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Sodium warfarin; Assigned to Arm(s): 1, 2
B: Intervention Type: DRUG; Name: Vitamin K antagonist (Coumarin anticoagulants); Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: Duration of anticoagulation; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Warfarin duration; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: Warfarin; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-blind Comparison of Atomoxetine Hydrochloride and Placebo for Symptoms of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents With Autism Spectrum Disorder
Brief Summary: The purpose of this study is to determine whether atomoxetine is effective in reducing ADHD (Attention Deficit/Hyperactivity Disorder) symptoms in children and adolescents with ASD (Autism Spectrum Disorder).


Options:
A: Arm Label: Lurasidone 20 mg; Type: EXPERIMENTAL; Interventions: Drug: Lurasidone 20 mg daily | Arm Label: Lurasidone 60 mg; Type: EXPERIMENTAL; Interventions: Drug: Lurasidone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Lurasidone 20 mg daily; Assigned to Arm(s): Lurasidone 20 mg | Intervention Type: DRUG; Name: Lurasidone; Assigned to Arm(s): Lurasidone 60 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Atomoxetine; Type: EXPERIMENTAL; Interventions: Drug: Atomoxetine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Atomoxetine; Assigned to Arm(s): Atomoxetine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: atomoxetine, Behavioral: Parent Management Training | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: atomoxetine | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Behavioral: Parent Management Training | Arm Label: 4; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: atomoxetine; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 3, 4 | Intervention Type: BEHAVIORAL; Name: Parent Management Training; Assigned to Arm(s): 1, 3
D: Arm Label: D-cycloserine; Type: EXPERIMENTAL; Interventions: Drug: D-cycloserine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: D-cycloserine; Assigned to Arm(s): D-cycloserine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-blind Comparison of Atomoxetine Hydrochloride and Placebo for Symptoms of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents With Autism Spectrum Disorder
Brief Summary: The purpose of this study is to determine whether atomoxetine is effective in reducing ADHD (Attention Deficit/Hyperactivity Disorder) symptoms in children and adolescents with ASD (Autism Spectrum Disorder).


Options:
A: Arm Label: IGF-1; Type: EXPERIMENTAL; Interventions: Drug: IGF-1 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo/saline | Intervention Type: DRUG; Name: IGF-1; Assigned to Arm(s): IGF-1 | Intervention Type: DRUG; Name: Placebo/saline; Assigned to Arm(s): Placebo
B: Arm Label: Atomoxetine; Type: EXPERIMENTAL; Interventions: Drug: Atomoxetine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Atomoxetine; Assigned to Arm(s): Atomoxetine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Intranasal Oxytocin (Syntocinon); Type: EXPERIMENTAL; Interventions: Drug: Intranasal Oxytocin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Intranasal Oxytocin; Assigned to Arm(s): Intranasal Oxytocin (Syntocinon) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Divalproex Sodium; Type: EXPERIMENTAL; Interventions: Drug: Divalproex sodium | Intervention Type: DRUG; Name: Divalproex sodium; Assigned to Arm(s): Divalproex Sodium | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-blind Comparison of Atomoxetine Hydrochloride and Placebo for Symptoms of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents With Autism Spectrum Disorder
Brief Summary: The purpose of this study is to determine whether atomoxetine is effective in reducing ADHD (Attention Deficit/Hyperactivity Disorder) symptoms in children and adolescents with ASD (Autism Spectrum Disorder).


Options:
A: Intervention Type: DRUG; Name: Risperidone; Assigned to Arm(s): N/A
B: Arm Label: Atomoxetine; Type: EXPERIMENTAL; Interventions: Drug: Atomoxetine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Atomoxetine; Assigned to Arm(s): Atomoxetine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Intervention Type: DRUG; Name: secretin, synthetic porcine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: secretin, biologically derived porcine; Assigned to Arm(s): N/A
D: Arm Label: citalopram hydrobromide; Type: EXPERIMENTAL; Interventions: Drug: citalopram hydrobromide | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Intervention Type: DRUG; Name: citalopram hydrobromide; Assigned to Arm(s): citalopram hydrobromide | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Rotational Atherectomy Prior to Taxus Stent Treatment for Complex Native Coronary Artery Disease. A Multicenter, Prospective, Randomized Controlled Trial.
Brief Summary: The primary purpose of this study is to evaluate the long term effects of the polymer-based slow-release paclitaxel-eluting stent (TAXUS; Boston Scientific), with or without prior rotablation, in an angiographically well defined group of patients with complex calcified coronary lesions.


Options:
A: Arm Label: Rotational Atherectomy + PES; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Rotational Atherectomy + PES | Arm Label: Standard Treatment (PES without Rotational Atherectomy); Type: ACTIVE_COMPARATOR; Interventions: Procedure: Standard Treatment (PES without Rotational Atherectomy) | Intervention Type: PROCEDURE; Name: Rotational Atherectomy + PES; Assigned to Arm(s): Rotational Atherectomy + PES | Intervention Type: PROCEDURE; Name: Standard Treatment (PES without Rotational Atherectomy); Assigned to Arm(s): Standard Treatment (PES without Rotational Atherectomy)
B: Arm Label: Pantheris Treatment Arm; Type: EXPERIMENTAL; Interventions: Device: Pantheris System | Intervention Type: DEVICE; Name: Pantheris System; Assigned to Arm(s): Pantheris Treatment Arm
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Device: PTA with placement of paclitaxel-eluting stent | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Device: PTA | Intervention Type: DEVICE; Name: PTA with placement of paclitaxel-eluting stent; Assigned to Arm(s): 1 | Intervention Type: DEVICE; Name: PTA; Assigned to Arm(s): 2
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Other: Percutaneous Transluminal Angioplasty | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Device: LifeStent NT™ Self-Expanding Peripheral Stent | Intervention Type: OTHER; Name: Percutaneous Transluminal Angioplasty; Assigned to Arm(s): 1 | Intervention Type: DEVICE; Name: LifeStent NT™ Self-Expanding Peripheral Stent; Assigned to Arm(s): 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of Inpatient Initiation of Carvedilol and Nurse Management on Health Outcomes in Vulnerable Heart Failure Patients (ECHO Study): a Randomized Trial
Brief Summary: The purpose of our study was to determine if a strategy of starting a heart medication (Beta-blocker) before patients leave the hospital and then being seen by a nurse manager would reduce subsequent hospitalizations compared to usual care.

Hypothesis: A nurse-directed heart failure management program with inpatient initiation of beta blockers will improve health outcomes in a vulnerable, predominantly Hispanic and African American population.


Options:
A: Intervention Type: BEHAVIORAL; Name: Re-Mission; Assigned to Arm(s): N/A
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Text messaging reminders | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Text messaging reminders; Assigned to Arm(s): 1
C: Intervention Type: BEHAVIORAL; Name: Home-based adherence monitoring; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: carvedilol plus nurse management; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Labor and Delivery Teamwork Intervention Trial
Brief Summary: A cluster-randomized controlled trial was conducted at 7 intervention and 8 control hospitals to evaluate the effect of teamwork training on the occurrence of adverse outcomes and processes of care in labor and delivery.


Options:
A: Intervention Type: BEHAVIORAL; Name: Labor and Delivery Team Coordination Course; Assigned to Arm(s): N/A
B: Arm Label: package; Type: EXPERIMENTAL; Interventions: Other: package of 3 interventions | Intervention Type: OTHER; Name: package of 3 interventions; Assigned to Arm(s): package
C: Arm Label: In situ simulation; Type: EXPERIMENTAL; Interventions: Other: In situ simulation | Arm Label: Off site simulation; Type: ACTIVE_COMPARATOR; Interventions: Other: Off site simulation | Intervention Type: OTHER; Name: In situ simulation; Assigned to Arm(s): In situ simulation | Intervention Type: OTHER; Name: Off site simulation; Assigned to Arm(s): Off site simulation
D: Arm Label: Standard care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: data strengthening, Behavioral: modified Safe childbirth checklist - control | Arm Label: Enhanced care (intervention); Type: EXPERIMENTAL; Interventions: Behavioral: data strengthening, Behavioral: modified Safe childbirth checklist - enhanced, Behavioral: PRONTO training, Behavioral: QI cycles | Intervention Type: BEHAVIORAL; Name: data strengthening; Assigned to Arm(s): Enhanced care (intervention), Standard care | Intervention Type: BEHAVIORAL; Name: modified Safe childbirth checklist - control; Assigned to Arm(s): Standard care | Intervention Type: BEHAVIORAL; Name: modified Safe childbirth checklist - enhanced; Assigned to Arm(s): Enhanced care (intervention) | Intervention Type: BEHAVIORAL; Name: PRONTO training; Assigned to Arm(s): Enhanced care (intervention) | Intervention Type: BEHAVIORAL; Name: QI cycles; Assigned to Arm(s): Enhanced care (intervention)

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Labor and Delivery Teamwork Intervention Trial
Brief Summary: A cluster-randomized controlled trial was conducted at 7 intervention and 8 control hospitals to evaluate the effect of teamwork training on the occurrence of adverse outcomes and processes of care in labor and delivery.


Options:
A: Arm Label: Full - Train/oxy&miso/ B&M/Mentor/Phone; Type: EXPERIMENTAL; Interventions: Other: Helping Mothers Survive - Bleeding After Birth training, Other: Helping Babies Breathe, Behavioral: Mentor, Behavioral: Phone, Drug: oxytocin and misoprostol, Device: Newborn bag and mask | Arm Label: Partial - Train/oxy & miso/ B&M/Mentor; Type: EXPERIMENTAL; Interventions: Other: Helping Mothers Survive - Bleeding After Birth training, Other: Helping Babies Breathe, Behavioral: Mentor, Drug: oxytocin and misoprostol, Device: Newborn bag and mask | Arm Label: Comparison - Train/oxy & miso/ B&M; Type: ACTIVE_COMPARATOR; Interventions: Other: Helping Mothers Survive - Bleeding After Birth training, Other: Helping Babies Breathe, Drug: oxytocin and misoprostol, Device: Newborn bag and mask | Intervention Type: OTHER; Name: Helping Mothers Survive - Bleeding After Birth training; Assigned to Arm(s): Comparison - Train/oxy & miso/ B&M, Full - Train/oxy&miso/ B&M/Mentor/Phone, Partial - Train/oxy & miso/ B&M/Mentor | Intervention Type: OTHER; Name: Helping Babies Breathe; Assigned to Arm(s): Comparison - Train/oxy & miso/ B&M, Full - Train/oxy&miso/ B&M/Mentor/Phone, Partial - Train/oxy & miso/ B&M/Mentor | Intervention Type: BEHAVIORAL; Name: Mentor; Assigned to Arm(s): Full - Train/oxy&miso/ B&M/Mentor/Phone, Partial - Train/oxy & miso/ B&M/Mentor | Intervention Type: BEHAVIORAL; Name: Phone; Assigned to Arm(s): Full - Train/oxy&miso/ B&M/Mentor/Phone | Intervention Type: DRUG; Name: oxytocin and misoprostol; Assigned to Arm(s): Comparison - Train/oxy & miso/ B&M, Full - Train/oxy&miso/ B&M/Mentor/Phone, Partial - Train/oxy & miso/ B&M/Mentor | Intervention Type: DEVICE; Name: Newborn bag and mask; Assigned to Arm(s): Comparison - Train/oxy & miso/ B&M, Full - Train/oxy&miso/ B&M/Mentor/Phone, Partial - Train/oxy & miso/ B&M/Mentor
B: Arm Label: EMONC: Community mobilization, HBLSS and Facility Improvement; Type: EXPERIMENTAL; Interventions: Behavioral: Community Mobilization, HBLSS and facility improvement | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Community Mobilization, HBLSS and facility improvement; Assigned to Arm(s): EMONC: Community mobilization, HBLSS and Facility Improvement
C: Arm Label: NRP Training (Intervention); Type: EXPERIMENTAL; Interventions: Procedure: Neonatal Resuscitation | Arm Label: Control; Type: OTHER; Interventions: Procedure: Neonatal Resuscitation | Intervention Type: PROCEDURE; Name: Neonatal Resuscitation; Assigned to Arm(s): Control, NRP Training (Intervention)
D: Intervention Type: BEHAVIORAL; Name: Labor and Delivery Team Coordination Course; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Improving Outcomes in Diabetic Nephropathy
Brief Summary: Kidney disease affects about one out of three people with diabetes mellitus, a common medical problem. Treatment of kidney disease with medications that lower blood pressure can slow the kidney disease but there is no known cure. This study is designed to test the hypothesis that certain combination-based blood pressure lowering regimens (of FDA approved medications) are better than single agent-based regimens for lowering blood pressure and further slowing or preventing progression of this incurable disease


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Eplerenone | Arm Label: 2; Type: NO_INTERVENTION; Interventions: Drug: Eplerenone | Intervention Type: DRUG; Name: Eplerenone; Assigned to Arm(s): 1, 2
B: Intervention Type: DRUG; Name: losartan 100 mg orally once daily; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: spironolactone 25 mg orally once daily; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: placebo once orally once daily; Assigned to Arm(s): N/A
C: Arm Label: Spironolactone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Spironolactone, Drug: Standard care | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Standard care | Arm Label: Observational; Type: OTHER; Interventions: Drug: Standard care | Intervention Type: DRUG; Name: Spironolactone; Assigned to Arm(s): Spironolactone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Standard care; Assigned to Arm(s): Observational, Placebo, Spironolactone
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Spironolactone; Type: EXPERIMENTAL; Interventions: Drug: Spironolactone | Intervention Type: DRUG; Name: Spironolactone; Assigned to Arm(s): Spironolactone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Reducing Sugar-Sweetened Beverage Consumption in Overweight Adolescents
Brief Summary: The primary aim of this study is to examine the effect of a multi-component intervention, designed to reduce consumption of sugar-sweetened beverages, on weight gain, total energy intake, and diet quality in adolescents. The secondary aim is to evaluate whether outcomes of the intervention differ between adolescents for whom 100% fruit juice vs. other products (i.e., soda, fruit punch, lemonade, iced tea, coffee drinks, energy drinks, sports drinks) constitutes the primary source of sugar from beverages.


Options:
A: Intervention Type: BEHAVIORAL; Name: Low glycemic index diet; Assigned to Arm(s): N/A
B: Intervention Type: BEHAVIORAL; Name: Internet-based intervention designed to reduce binge eating and improve healthy weight regulation; Assigned to Arm(s): N/A
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Reduction of sugar-sweetened beverage consumption | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Reduction of sugar-sweetened beverage consumption; Assigned to Arm(s): 1
D: Arm Label: usual care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention - Web; Type: EXPERIMENTAL; Interventions: Behavioral: Weekly access to interactive web site | Arm Label: Intervention - Group; Type: EXPERIMENTAL; Interventions: Behavioral: Group | Arm Label: Intervention - Cell Phone; Type: EXPERIMENTAL; Interventions: Behavioral: Cell Phone | Intervention Type: BEHAVIORAL; Name: Cell Phone; Assigned to Arm(s): Intervention - Cell Phone | Intervention Type: BEHAVIORAL; Name: Weekly access to interactive web site; Assigned to Arm(s): Intervention - Web | Intervention Type: BEHAVIORAL; Name: Group; Assigned to Arm(s): Intervention - Group

Answer: C